Top 1% Stock, Hims & Hers Health, Dives On Lackluster Outlook The company recently inked a deal with Novo Nordisk. But will that bolster current-quarter sales?
Hims & Hers Names New COO. Stock Rallies. Hims stock rose Monday after the telehealth program named technology industry veteran Nader Kabbani as its new chief operating officer.
Hims & Hers: The Next Amazon? Novo Nordisk Might Be Prime Delivery Hims & Hers Health Inc. (
NYSE:HIMS ) partners with Novo Nordisk to offer affordable weight-loss drug, positioning itself to expand into other healthcare areas.
Pony AI, Hims & Hers And Frontdoor Are Among Top 11 Mid-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio? Top performers last week: PONY, HIMS, ODD, MTSR, CGON, KNSA, KC, FTDR, ATI, PRDO, and IRTC. Have you invested in them?
Amgen's Better Than Expected Q1 Earnings Take Backseat As Eyes Are On MariTide Obesity Data Analysts highlight MariTide's upcoming updates and near-term catalysts, while Amgen's price targets shift amid steady outlook and investor caution.
Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market potential.
Why Is Novo Nordisk Stock Trading Higher On Friday? Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease affecting patients with obesity.
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors.
The Top 3 Stock Picks at the World’s Greatest Hedge Fund See which three stocks the world's most successful hedge fund, which generated returns of +30% for decades, had the biggest stakes in at the end of 2024.
CVS Caremark To Place Novo Nordisk's Wegovy On Preferred Coverage For GLP-1 Weight Loss Treatment Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access initiatives.
Why Novo Nordisk Stock Popped Today Guess WHO thinks Novo Nordisk stock is a buy now?
CVS Health Partners With Wegovy Maker Novo Nordisk, Hikes 2025 Guidance CVS Health topped Q1 estimates with $94.59 billion in revenue and raised 2025 EPS outlook to $6.00–$6.20 amid strong Medicare performance.
Where Is Hims & Hers Stock Headed After Wegovy Tie-Up? Retail Traders Bet On Rebound To Over 2-Month High Needham called the tie-up a “groundbreaking partnership” and said it alleviates investor concerns around Hims’ ability to hit its 2025 weight loss revenue guidance.
Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform Hims & Hers partners with Novo Nordisk to offer Wegovy access online with clinical support, expanding its weight loss care and revenue strategy.
Hims & Hers, LifeMD Stocks Surge On Novo Nordisk's Plan To Sell Wegovy Via Telehealth Operators Patients will be able to access Novo Nordisk’s direct-to-patient online pharmacy, NovoCare, through the telehealth providers.
Hims Stock Catapults After Inking Deal To Sell Novo Nordisk's Wegovy The companies will collaborate to improve access to weight-loss drugs in the U.S.
Novo Nordisk’s Weight-Loss Drug Wegovy Launched In Thailand, Marks Entry Into Southeast Asia Enrico Canal Bruland, vice president and general manager of Novo's Thai subsidiary, told Reuters that the firm received approval from the Thai FDA in 2023.
Pfizer Stock Climbs Pre-Market On Bladder Cancer Trial Success: Retail Digests Data Ahead Of Q1 Print Pfizer highlighted positive late-stage results for its experimental bladder cancer drug, sasanlimab, as it looks to strengthen its oncology portfolio and offset losses from recent setbacks in its weight-loss drug program.
